AIMS/HYPOTHESIS: Phosphoinositide 3-kinase (PI 3K) plays a central part in the mediation of insulin-stimulated glucose disposal. No genetic studies of this enzyme in human syndromes of severe insulin resistance have been previously reported. METHODS: Phosphoinositide 3-kinase p85 alpha regulatory subunit cDNA was examined in 20 subjects with syndromes of severe insulin resistance by single strand conformational polymorphism and restriction fragment length polymorphism analyses. Insulin-stimulated phosphoinositide 3-kinase activity and recruitment into phosphotyrosine complexes of variants of p85 alpha were studied in transiently transfected HEK293 cells. Phosphopeptide binding characteristics of wild-type and mutant p85 alpha-GST fusion proteins were examined by surface plasmon resonance. RESULTS: The common p85 alpha variant, Met326I1e, was identified in 9 of the 20 subjects. Functional studies of the Met326Ile variant showed it to have equivalent insulin-stimulated lipid kinase activity and phosphotyrosine recruitment as wild-type p85 alpha. A novel heterozygous mutation, Arg409Gln, was detected in one subject. Within the proband's family, carriers of the mutation had a higher median fasting plasma insulin (218 pmol/l) compared with wild-type relatives (72 mol/l) (n = 8 subjects, p = 0.06). The Arg409Gln p85 alpha subunit was associated with lower insulin-stimulated phosphoinositide 3-kinase activity compared with wild-type (mean reduction 15%, p < 0.05, n = 5). The recruitment of Arg409Gln p85 alpha into phosphotyrosine complexes was not significantly impaired. GST fusion proteins of wild-type and mutant p85 alpha showed identical binding to phosphopeptides in surface plasmon resonance studies. CONCLUSION/ INTERPRETATION: Mutations in p85 alpha are uncommon in subjects with syndromes of severe insulin resistance. The Met326Ile p85 alpha variant appears to have no functional effect on the insulin-stimulated phosphoinositide 3-kinase activity. The impaired phosphoinositide 3-kinase activity of the Arg409Gln mutant suggests that it could contribute to the insulin resistance seen in this family.
AIMS/HYPOTHESIS: Phosphoinositide 3-kinase (PI 3K) plays a central part in the mediation of insulin-stimulated glucose disposal. No genetic studies of this enzyme in human syndromes of severe insulin resistance have been previously reported. METHODS: Phosphoinositide 3-kinase p85 alpha regulatory subunit cDNA was examined in 20 subjects with syndromes of severe insulin resistance by single strand conformational polymorphism and restriction fragment length polymorphism analyses. Insulin-stimulated phosphoinositide 3-kinase activity and recruitment into phosphotyrosine complexes of variants of p85 alpha were studied in transiently transfected HEK293 cells. Phosphopeptide binding characteristics of wild-type and mutant p85 alpha-GST fusion proteins were examined by surface plasmon resonance. RESULTS: The common p85 alpha variant, Met326I1e, was identified in 9 of the 20 subjects. Functional studies of the Met326Ile variant showed it to have equivalent insulin-stimulated lipid kinase activity and phosphotyrosine recruitment as wild-type p85 alpha. A novel heterozygous mutation, Arg409Gln, was detected in one subject. Within the proband's family, carriers of the mutation had a higher median fasting plasma insulin (218 pmol/l) compared with wild-type relatives (72 mol/l) (n = 8 subjects, p = 0.06). The Arg409Gln p85 alpha subunit was associated with lower insulin-stimulated phosphoinositide 3-kinase activity compared with wild-type (mean reduction 15%, p < 0.05, n = 5). The recruitment of Arg409Gln p85 alpha into phosphotyrosine complexes was not significantly impaired. GST fusion proteins of wild-type and mutant p85 alpha showed identical binding to phosphopeptides in surface plasmon resonance studies. CONCLUSION/ INTERPRETATION: Mutations in p85 alpha are uncommon in subjects with syndromes of severe insulin resistance. The Met326Ile p85 alpha variant appears to have no functional effect on the insulin-stimulated phosphoinositide 3-kinase activity. The impaired phosphoinositide 3-kinase activity of the Arg409Gln mutant suggests that it could contribute to the insulin resistance seen in this family.
Authors: Lazaros C Foukas; Caroline A Beeton; Jorgen Jensen; Wayne A Phillips; Peter R Shepherd Journal: Mol Cell Biol Date: 2004-02 Impact factor: 4.272
Authors: David A Dyment; Amanda C Smith; Diana Alcantara; Jeremy A Schwartzentruber; Lina Basel-Vanagaite; Cynthia J Curry; I Karen Temple; William Reardon; Sahar Mansour; Mushfequr R Haq; Rodney Gilbert; Ordan J Lehmann; Megan R Vanstone; Chandree L Beaulieu; Jacek Majewski; Dennis E Bulman; Mark O'Driscoll; Kym M Boycott; A Micheil Innes Journal: Am J Hum Genet Date: 2013-06-27 Impact factor: 11.025
Authors: Katrine Almind; Laurent Delahaye; Torben Hansen; Emmanuel Van Obberghen; Oluf Pedersen; C Ronald Kahn Journal: Proc Natl Acad Sci U S A Date: 2002-02-12 Impact factor: 11.205
Authors: Ryaz B Chagpar; Philip H Links; M Chris Pastor; Levi A Furber; Andrea D Hawrysh; M Dean Chamberlain; Deborah H Anderson Journal: Proc Natl Acad Sci U S A Date: 2010-03-08 Impact factor: 11.205
Authors: M Dean Chamberlain; Tim Chan; Jennifer C Oberg; Andrea D Hawrysh; Kristy M James; Anurag Saxena; Jim Xiang; Deborah H Anderson Journal: J Biol Chem Date: 2008-04-03 Impact factor: 5.157
Authors: Ting-Yuan David Cheng; Jyoti Shankar; Gary Zirpoli; Michelle R Roberts; Chi-Chen Hong; Elisa V Bandera; Christine B Ambrosone; Song Yao Journal: Cancer Causes Control Date: 2016-06-17 Impact factor: 2.506
Authors: Isabel Huang-Doran; Patsy Tomlinson; Felicity Payne; Alexandra Gast; Alison Sleigh; William Bottomley; Julie Harris; Allan Daly; Nuno Rocha; Simon Rudge; Jonathan Clark; Albert Kwok; Stefano Romeo; Emma McCann; Barbara Müksch; Mehul Dattani; Stefano Zucchini; Michael Wakelam; Lazaros C Foukas; David B Savage; Rinki Murphy; Stephen O'Rahilly; Inês Barroso; Robert K Semple Journal: JCI Insight Date: 2016-10-20
Authors: Inês Barroso; Jian'an Luan; Rita P S Middelberg; Anne-Helen Harding; Paul W Franks; Rupert W Jakes; D Clayton; Alan J Schafer; Stephen O'Rahilly; Nicholas J Wareham Journal: PLoS Biol Date: 2003-10-13 Impact factor: 8.029